Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
NexgenRxNEGXF 51 EV-to-EBIT is 13.49 as of Aug. 13, 2026, which is 4% below its 10-year median of 14.05. GuruFocus rates NEGXF with a GF Score™ of 51/100 and a GF Value™ of $0.27 (Modestly Overvalued). The stock has 3 warning signs investors should review. Among 472 Healthcare Providers & Services companies, NexgenRx ranks better than 57.84% on this metric.
The historical rank and industry rank for NexgenRx's EV-to-EBIT or its related term are showing as below:
NEGXF'
s EV-to-EBIT Range Over the Past 10 Years
Min: -2182.64 Med: 14.05 Max: 14537.5
Current: 15.02
During the past 13 years, the highest EV-to-EBIT of NexgenRx was 14537.50. The lowest was -2182.64. And the median was 14.05.
NEGXF's EV-to-EBIT is ranked better than 57.84% of 472
companies
in the Healthcare Providers & Services industry
Industry Median: 15.75
vs NEGXF: 15.02
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
NexgenRx's Enterprise Value for the quarter that ended in Mar. 2026 was $17.22 Mil.
NexgenRx's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $1.93 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NexgenRx EV-to-EBIT Related Terms
NexgenRx EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for NexgenRx's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Health Information Services subindustry, NexgenRx's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
NexgenRx EV-to-EBIT vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, NexgenRx's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where NexgenRx's EV-to-EBIT falls into.
NexgenRx's current Enterprise Value is $26.09 Mil.
NexgenRx's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $1.93 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NexgenRx (NEGXF) has a EV-to-EBIT of 13.49 as of Aug. 13, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on NexgenRx and its competitors. This is near median its historical median of 14.05. According to the industry distribution chart, NexgenRx ranks #199 out of 472 companies in the Healthcare Providers & Services industry, placing it in the top 42.2%.
Is NexgenRx's EV-to-EBIT too high?
NexgenRx's current EV-to-EBIT of 13.49 is near median its 10-year median of 14.05. The Healthcare Providers & Services industry median EV-to-EBIT is 15.75. NexgenRx's value of 13.49 is 14.3% below this industry median. Based on the distribution chart, NexgenRx ranks #199 out of 472 companies in the Healthcare Providers & Services industry, which is above the industry midpoint. Overall, NexgenRx has a GF Score™ of 51/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does NexgenRx's EV-to-EBIT compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, NexgenRx ranks #199 out of 472 companies for EV-to-EBIT. This puts NexgenRx in the upper half of its industry. The industry median EV-to-EBIT is 15.75. NexgenRx's value of 13.49 is 14.3% below this benchmark. While the company's 10-year median is 14.05 vs. the industry median of 15.75, NexgenRx has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Healthcare Providers & Services company?
The median EV-to-EBIT among Healthcare Providers & Services companies is 15.75, based on 472 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. NexgenRx's current EV-to-EBIT of 13.49 is 14.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on NexgenRx and its competitors. For the Healthcare Providers & Services industry, the median EV-to-EBIT is 15.75 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. NexgenRx's current EV-to-EBIT is 13.49, which is near median its own 10-year median of 14.05. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NexgenRx stock overvalued right now?
Based on GuruFocus' analysis, NexgenRx (NEGXF) is currently considered Modestly Overvalued. The stock's GF Value™ is $0.27, compared to a current price of $0.33 — trading 20.4% above its estimated fair value. The current EV-to-EBIT is 13.49, which is near median its 10-year median of 14.05 and 14.3% below the Healthcare Providers & Services industry median of 15.75. NexgenRx's overall GF Score™ is 51/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For NexgenRx (NEGXF), the current EV-to-EBIT is 13.49 as of Aug. 13, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is NexgenRx (NEGXF) Overvalued in 2026?
Based on GuruFocus' analysis, NexgenRx stock appears to be overvalued.
The current stock price of $0.33 is trading 20.4% above its estimated GF Value™ of $0.27.
GuruFocus considers NexgenRx to be Modestly Overvalued.
Key valuation signals for NEGXF:
EV-to-EBIT: 13.49 (near median its 10-year median of 14.05)
GF Value™: $0.27 vs. price of $0.33 (20.4% above fair value)
Industry Position: 14.3% below the Healthcare Providers & Services median (#199 of 472)
No single metric tells the full story. See the NEGXF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
NexgenRx Inc administers, adjudicates, and pays drug, dental and other extended health-care claims for the beneficiaries of health benefit plans underwritten by its customers using proprietary computer software and also provides ancillary services. The various solutions offered by the company include: NexSys, a fully integrated rules-based adjudication platform for real-time processing of drug, dental, and extended health benefit claims; NexAdmin, which enables sponsors to take complete control of benefit plan administration; and NexPSPAssist, a service that helps Patient Support Programs (PSP) to optimize their deliverables to their manufacturer clients. The company has only one operating segment - benefits administration services.
51GF Score
Get the complete analysis for NEGXF
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NEGXF has been successfully added to your 
